Veracyte Inc (VCYT) financials
Veracyte revenue and earnings by year
Veracyte's revenue was $517 million in the fiscal year to December 31, 2025, up 16.0% from the year before. Net income was $66.4 million, 12.8% of revenue. Since the fiscal year to December 31, 2016, revenue has grown 25.9% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 10 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 517 | 446 | 361 | 297 | 220 | 117 | 120 | 92 | 72 | 65 |
| Revenue growth | 16.0% | 23.5% | 21.8% | 35.1% | 86.8% | -2.4% | 30.8% | 27.9% | 10.6% | — |
| Gross profit | 363 | 298 | 230 | 176 | 145 | 76 | 84 | 59 | 44 | 40 |
| Gross margin | 70.1% | 66.9% | 63.6% | 59.2% | 66.1% | 64.7% | 69.7% | 64.0% | 60.8% | 60.9% |
| Operating income | 58 | 16 | -86 | -41 | -82 | -35 | -15 | -22 | -27 | -29 |
| Operating margin | 11.2% | 3.6% | -23.8% | -13.9% | -37.3% | -30.1% | -12.6% | -24.2% | -36.9% | -44.3% |
| Net income | 66 | 24 | -74 | -37 | -76 | -35 | -13 | -23 | -31 | -31 |
| Net margin | 12.8% | 5.4% | -20.6% | -12.3% | -34.4% | -29.7% | -10.5% | -25.0% | -43.1% | -48.2% |
| Diluted EPS | $0.82 | $0.31 | -$1.02 | -$0.51 | -$1.11 | -$0.68 | -$0.28 | -$0.63 | -$0.91 | -$1.08 |
| Free cash flow | 127 | 64 | 34 | -1 | -37 | -13 | -6 | -15 | -25 | -32 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open VCYT in Markets.
How Veracyte makes money
Revenue by segment in the quarter to June 30, 2026, as the company reports it.
| Segment | Revenue | Share |
|---|---|---|
| Testing | $146M | 96.9% |
| Product | $3.86M | 2.6% |
| Biopharmaceutical & Other | $802K | 0.5% |
See also: VCYT valuation and P/E history · VCYT returns
No forecast, no recommendation. This page describes Veracyte Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.